SensiCab: Efficacy Study Evaluating Chemotherapy in Prostate Cancer
SensiCab: Efficacy Study Evaluating Chemotherapy in Prostate Cancer
Project number : 264481
Created by: Anna Messing Eriksson, 2019-03-07
Last revised by: Anna Messing Eriksson, 2019-03-07
Project created in: FoU Region Örebro län

PublishedPublished
2013-11-08
Rekrytering/datainsamling pågår

Registeranmälan

  1. SensiCab, Registeranmälan
  2. SensiCab: Efficacy Study Evaluating Chemotherapy in Prostate Cancer, Projektbeskrivning

Titel och sammanfattning

Akronym

SensiCab

Populärvetenskaplig sammanfattning

This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression.

It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.

This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease

Sammanfattning på engelska

This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression.

It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.

This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease

Projektspecifik information

Ämnesord

checked Cancer och onkologi
checked Urologi och njurmedicin


(Only selected options are displayed. Click here to display all options)

Studietyp

Prövning av behandling

Fas

III

Randomiserad studie

Ja

Diagnoskod för huvuddiagnos

C60-C63 Maligna tumörer i de manliga könsorganen

Multicenterstudie

Ja

EudraCTnr

2011-003078-10

ClinicalTrials.gov

NCT01978873

Inklusionsstatus

 Planerat antalAntal tillfrågadeScreen-failureAntal randominserade
n=Totalt 400 patienter   

Vetenskaplig sammanfattning

This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression.

It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment.

This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease. Two therapeutic approaches will be compared in this two-arm randomized clinical trial. The control Arm A provides hormonal therapy alone. The experimental Arm B involves treatment with hormone therapy + Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable or responding disease up to 10 cycles. For the schematic representation of study design please see Section 7.3.1.

Subjects with primary metastatic or N+ or high risk disease (PSA>100) will be eligible. The primary endpoint of the trial is overall survival.

Based on the yearly number of prostate cancer patients who are diagnosed with metastatic or high risk disease, approximately 1200 men per year (if +15% improvement)are potential candidates for this approach in the Scandinavian countries .

Involverade parter

Arbetsplats

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Område opererande och onkologi - Urologiska kliniken workplace verified by Region Örebro län on 2018-06-14

Projektägare är huvudprövare eller ansvarig forskare

checked Ja


(Only selected options are displayed. Click here to display all options)

Sponsor

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Område opererande och onkologi - Urologiska kliniken workplace verified by Region Örebro län on 2018-06-14

SensiCab: Efficacy Study Evaluating Chemotherapy in Prostate Cancer, from FoU Region Örebro län
http://www.researchweb.org/is/en/fourol/project/264481